A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer. (May 2017)

• Record Type: Journal Article
• Authors: Bersani, Cinzia; Mints, Michael; Tertipis, Nikolaos; Haeggblom, Linnea; Sivars, Lars; Ährlund-Richter, Andreas; Vlastos, Andrea; Smedberg, Cecilia; Grün, Nathalie; Munck-Wikland, Eva; Näsman, Anders; Ramqvist, Torbjörn; Dalianis, Tina
• Is Part Of: Oral oncology. Volume 68(2017)
• Page Start: 53
• Page End: 59
• Publication Date: 2017-05
• Subjects: HPV -- Oropharyngeal cancer tonsillar cancer -- Base of tongue cancer -- Biomarkers -- Survival; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2017.03.007
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: CD8 + TILs, age, T-stage <3, presence of HPV16 E2 mRNA were predictors for survival. Having three of above markers captured non-relapsing patients with a PPV of 97%. Radiotherapy, with or without oncological or targeted therapy, had similar outcome. Abstract: Objective: Head-neck cancer therapy has become intensified. With radiotherapy alone, 3-year disease-free survival (DFS) is 80% for HPV-positive TSCC/BOTSCC and better for patients with favorable characteristics, suggesting therapy could be tapered for some, decreasing side-effects. Therefore, we built a model to predict progression-free survival for patients with HPV-positive TSCC and BOTSCC. Material and methods: TSCC/BOTSCC patients treated curatively between 2000 and 2011, with HPV16 DNA/E7 mRNA positive tumors examined for CD8 + TILs, HPV16 mRNA and HLA class I expression were included. Patients were split randomly 65/35 into training and validation sets, and LASSO regression was used to select a model in the training set, the performance of which was evaluated in the validation set. Results: 258 patients with HPV DNA/E7 mRNA positive tumors could be included, 168 and 90 patients in the respective sets. No treatment improved prognosis compared to radiotherapy alone. CD8 + TIL counts and young age were the strongest predictors of survival, followed by T-stage <3 and presence of HPV16 E2 mRNA. The model had an area under curve (AUC) of 76%. A model where the presence of three of four of these markers defined good prognosis captured 56% of non-relapsing patients with a positive predictive value of 98% in the validation set. Furthermore, the model identified 35% of our cohort that was overtreated and could safely have received de-escalated therapy. Conclusion: CD8 + TIL counts, age, T-stage and E2 expression could predict progression-free survival, identifying patients eligible for randomized trials with milder treatment, potentially reducing side effects without worsening prognosis.